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Abstract.
Background: The human branched chain aminotransferases (hBCATm, mitochondrial and hBCATc, cytosolic) are major
contributors to brain glutamate production. This excitatory neurotransmitter is thought to contribute to neurotoxicity in neurode-
generative conditions such as Alzheimer’s disease (AD) but the expression of hBCAT in this disease has not previously been
investigated.
Objective: The objective of investigating hBCAT expression is to gain insight into potential metabolic pathways that may be
dysregulated in AD brain, which would contribute to glutamate toxicity.
Methods: Western blot analysis and immunohistochemistry were used to determine the expression and localization of hBCAT
in postmortem frontal and temporal cortex from AD and matched control brains.
Results: Western blot analysis demonstrated a significant regional increase in hBCATc expression in the hippocampus (↑ 36%;
p-values of 0.012), with an increase of ↑ 160% reported for hBCATm in the frontal and temporal cortex (p-values = 4.22 × 10−4
and 2.79 × 10−5, respectively) in AD relative to matched controls, with evidence of post-translational modifications to hBCATm,
more prominent in AD samples. Using immunohistochemistry, a significant increase in immunopositive labelling of hBCATc
was observed in the CA1 and CA4 region of the hippocampus (p-values = 0.011 and 0.026, respectively) correlating with western
blot analysis. Moreover, the level of hBCATm in the frontal and temporal cortex correlated significantly with disease severity,
as indicated by Braak staging (p-values = 5.63 × 10−6 and 9.29 × 10−5, respectively).
Conclusion: The expression of the hBCAT proteins is significantly elevated in AD brain. This may modulate glutamate
production and toxicity, and thereby play a role in the pathogenesis of the disease.
Keywords: Alzheimer’s disease, glutamate metabolism, hBCAT
INTRODUCTION
In Alzheimer’s disease (AD), amyloid- accumula-
tion is thought to initiate a cascade of processes that
culminate in synaptic and neuronal damage, the hall-
marks of neurodegenerative disease [1]. Although the
sequence of events which govern this are not well
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understood, several metabolic processes are thought
to be involved including cellular stress, glutamate
toxicity, calcium overload, protein misfolding, and
dysregulation of autophagy [2–8]. Under normal phys-
iological conditions, glutamate plays a key role in
dendrite and synapse formation and, through gluta-
matergic transmission, is essential for memory and
learning [9]. However, high levels of extracellular glu-
tamate at synapses result in neurotoxicity, thought to
be mediated largely through excessive influx of Ca++
[4]. There is also evidence that excitotoxicity leads to
ISSN 1387-2877/15/$35.00 © 2015 – IOS Press and the authors. All rights reserved
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increased expression of tau protein, neuronal degener-
ation, and cell death [10–13].
The branched chain aminotransferase (BCAT) pro-
teins are key metabolic proteins responsible for 30% of
de novo glutamate synthesis in rat neurons [14]. They
catalyze the reversible transamination of the branched
chain amino acids (BCAAs) leucine, isoleucine, and
valine to their respective branched chain -ketoacids
and glutamate (Scheme 1) [15]. These amino acids can
cross the blood-brain barrier and have been demon-
strated to act as nitrogen donors for the synthesis of
glutamate and glutamine in brain explants and in pri-
mary neuronal cultures [16, 17]. The second step in
this metabolic pathway, which is considered the rate
limiting step, involves the irreversible oxidative decar-
boxylation of the branched chain -keto acids into
co-enzyme A derivatives; catalyzed by the branched-
chain -keto acid dehydrogenase complex (BCKD)
[18]. This complex is composed of three catalytic
subunits, E1, E2, and E3. Mutations in the genes of
the BCKD complex cause maple syrup urine disease
(MSUD) [19]. This autosomal recessive disorder of
infancy or childhood is characterized by a build-up of
both BCAAs and their respective keto-acid derivatives
that are neurotoxic to cells, resulting in neurological
dysfunction, seizures, and death [19, 20]. Thus, accu-
mulation of products of BCAA metabolism, the-keto
acids and glutamate, leads to loss of neuronal integrity
that has severe clinical consequences.
In humans (hBCAT) two isoforms predominate:
a ubiquitous mitochondrial isoform, hBCATm (41
730 Da), and a largely neuron-specific cytosolic iso-
form, hBCATc (43 400 Da) [21]. Two other variants
of hBCATm have also been reported but are not well
characterized, the first isolated from placental tissue
and the second a splice variant that acts as a co-
repressor of thyroid hormone nuclear receptors [22,
23]. In humans and rodents, hBCATc is predominantly
found in the soma and proximal dendrites of gluta-
matergic and GABAergic neuronal cells, in keeping
with its role in contributing to the storage and metabolic
pools of glutamate, which is in turn decarboxylated in
GABAergic neurons to form GABA [24–26]. Immuno-
histochemical labelling of hBCATm in rat astrocytes
led to the development of the hypothetical model of
nitrogen shuttling between neurons and glial cells
(Fig. 1) [27–29]. In brief, transamination supports the
glutamate/glutamine cycle, which operates between
neuronal and astrocytic cells, to compensate for glu-
tamate ‘lost’ during oxidation in astrocytes. Here, it
was proposed that in astrocytes, transamination oper-
ates in the direction of glutamate production, whereas
the reverse was suggested in neuronal cells, ultimately
facilitating the transfer of BCAA nitrogen between
the two cell types and providing nitrogen for gluta-
mate/glutamine synthesis (Fig. 1A) [14, 29]. However,
in human brain tissue we showed that hBCATm is
localized to the brain vasculature rather than astrocytes
as observed in rat [26]. As hBCAT is expressed in glu-
tamatergic neurons, we proposed that transamination
contributes to glutamate synthesis and the expression
of hBCATm in the endothelial cells of the vascula-
ture supports astrocytic regulation of glutamate uptake
from the synaptic cleft (Fig. 1B) [26, 30].
Although hBCATs play a pivotal role in brain
glutamate metabolism, their possible contribution to
diseases associated with glutamate toxicity (thought to
be relevant to the pathogenesis of a range of neurode-
generative diseases) has not previously been evaluated
[2, 3, 9]. In this study we have investigated the cel-
lular distribution and expression of the hBCATs in
postmortem brain tissue from subjects with AD and
matched controls. We provide the first evidence that the
hBCAT proteins show regional upregulation in AD rel-
ative to age-matched controls. Not only is upregulation
evident but there is also evidence of differential post-
translation modification of hBCATm in AD, which
correlates with Braak stage, indicating a link with dis-
ease severity.
MATERIALS AND METHODS
Materials
Peroxidase substrate, 3,3′-diaminobenzidine
(DAB), Vectashield hard-set fluorescent mountant,
goat polyclonal antibody to rabbit IgG, biotin-labelled
secondary polyclonal antibody to IgG, and avidin
(Vectastain ABC kit) were obtained from Vector labs
(Peterborough, UK). Rabbit polyclonal antibodies to
hBCATc and hBCATm were purchased from Insight
Biotechnology limited (Wembley, UK). Mouse mon-
oclonal antibody to hBCATm was purchased from
Abcam (Cambridge, UK). We previously demon-
strated the specificity of the hBCATc and hBCATm
antibodies for western blotting and immunohistochem-
istry [26]. Alexafluor 488 and 647 were purchased from
Invitrogen (Paisley, UK). Mouse monoclonal antibody
to detect S-glutathionylation (Source Bioscience, UK).
Chemiluminescent HRP substrate was purchased from
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Fig. 1. Branched chain amino acid metabolism. Rodent model: The glutamate/glutamine cycle (dotted lines) operates to sustain neuronal
glutamate. However, some glutamate taken up by astrocytes is oxidized and this ‘lost’ glutamate is replenished by transamination reaction. In
astrocytes, transamination operates in the direction of glutamate production, whereas the reverse was suggested in neuronal cells, ultimately
facilitating the transfer of BCAA nitrogen between the two cell types and providing nitrogen for glutamate/glutamine synthesis [14, 29]. Human
model: In human brain tissue, hBCATm is localized to the endothelial cells of the vasculature [26]. Here, hBCATc transamination is considered
to contribute to glutamate production, as hBCATc is expressed in glutamatergic neurons, and the role of hBCATm in the vasculature supports
astrocytic regulation of glutamate uptake from the synaptic cleft [26] (reviewed in [30]).
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Millipore (Watford, UK) and mouse monoclonal anti-
body to glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) from Santa Cruz (Canada). All other
chemicals were obtained from Fisher Scientific
(Loughborough, UK) or Sigma-Aldrich (Dorset, UK).
Brain tissue preparation
The study was approved by North Somerset and
South Bristol Research Ethics Committee, Bristol, UK.
All brain tissue used in this study was from brains
donated to the South West Dementia Brain Bank at the
University of Bristol, UK. For western blot analysis,
40 AD brains and 40 age- and gender-matched controls
with both shorter and longer term postmortem delays
were assessed (Tables 1, 2). For immunohistochem-
istry, 30 AD brains and 30 age- and gender-matched
controls were studied (Table 3). The right cerebral
hemisphere, half brainstem and half cerebellum had
been fixed in 10% buffered formalin for 3 weeks before
being extensively sampled for paraffin histology and
neuropathological assessment by Prof. Seth Love, con-
sultant neuropathologist. The left hemibrain had been
sliced and frozen at −80◦C. All AD cases had a diag-
nosis of definite AD according to the Consortium to
Establish a Registry for AD criteria, and a Braak tan-
gle stage of IV, V, or VI. Controls did not have a
history of dementia and did not have any neuropatho-
logical abnormalities apart from occasional tangles in
the transentorhinal region and hippocampus in a few
cases (i.e., all had a Braak tangle stage of III or less).
Subject details are summarized in Tables 1–3.
Paraffin sections 7m in thickness were taken from
the right temporal lobe in the coronal plane of the lat-
eral geniculate body. The sections encompassed the
hippocampus, parahippocampal, and fusiform gyri.
From some brains, sections of the cerebellum were
also taken as an internal control as this region does
not show evidence of AD pathology apart from occa-
sional diffuse plaques. The sections were subsequently
processed for immunohistochemistry as described.
For western blot analysis, 250 mg of tissue from
the left temporal, frontal cortex, and hippocam-
pus was collected in RNase free tubes. For protein
Table 1
Alzheimer’s disease and control cases used in western blot analysis of hBCATc and hBCATm. All cases chosen had a postmortem (PM) delay
of less than 72 h, had no significant comorbidities (such as vascular dementia or Parkinson’s disease), and were age- and gender-matched
Case Age Gender Braak PM delay Case Age Gender Braak PM delay
AD 1 95 M 4 27 Control 1 93 M 3 38
AD 2 89 F 5 39 Control 2 88 F 0 72
AD 3 88 F 6 64 Control 3 88 F 2 28
AD 4 84 F 6 20.5 Control 4 84 F 1 17
AD 5 80 M 4 24 Control 5 80 M 0 46
AD 6 80 F 5 50 Control 6 80 F 0 72
AD 7 69 M 6 72 Control 7 69 M 2 66
AD 8 65 M 5 39 Control 8 64 M 0 16
AD 9 86 F 5 73 Control 9 89 F 2 15
AD 10 64 M 5 67 Control 10 64 M 2 12
AD 11 70 F 6 25 Control 11 70 M 2 50
AD 12 71 M 6 30 Control 12 71 M 1 25
AD 13 71 F 5 67 Control 13 72 F 0 24
AD 14 72 M 6 65 Control 14 72 M 1 42
AD 15 73 M 5 17 Control 15 73 M 1 33
AD 16 74 M 5 48 Control 16 73 M 2 36
AD 17 74 M 5 50 Control 17 73 M 3 35
AD 18 74 F 6 12 Control 18 73 F 1 59
AD 19 74 M 5 24 Control 19 75 M 2 48
AD 20 74 M 4 55 Control 20 75 M 3 6
AD 21 91 M 3 43 Control 21 92 M 2 34
AD 22 93 M 6 20 Control 22 94 M 2 40
AD 23 83 F 5 5 Control 23 83 F 2 24
AD 24 89 F 5 28 Control 24 89 F 3 47
AD 25 96 F 4 53 Control 25 94 F 2 21
AD 26 85 M 6 50 Control 26 85 M 2 31
AD 27 76 M 5 11 Control 27 76 M 2 23
AD 28 78 M 6 50 Control 28 78 M 1 48
AD 29 78 M 5 22 Control 29 78 M 2 12
AD 30 61 M 5 38 Control 30 62 M 0 4
Average 78.57 11 (F): 19 (M) 5.13 39.62 78.57 10 (F): 20 (M) 1.53 34.80
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Table 2
Alzheimer’s disease (AD) and control cases used in western blot analysis of hBCATc and hBCATm. All cases chosen had a postmortem (PM)
delay of less than 15 h, had no significant comorbidities (such as vascular dementia or Parkinson’s disease) and were age- and gender-matched
Case Age Gender Braak PM delay Case Age Gender Braak PM delay
AD 31 76 M 5 11 Control 31 75 M 3 6
AD 32 69 M 5 12 Control 32 77 M 3 10
AD 33 81 M 6 4 Control 33 81 M 2 3
AD 34 86 M 6 11.5 Control 34 88 F 3 15
AD 35 74 F 6 12 Control 35 74 F 0 12
AD 36 83 F 5 5 Control 36 89 F 2 15
AD 37 83 M 5 11 Control 37 82 M 2 3
AD 38 80 M 5 5 Control 38 78 M 2 12
AD 39 64 M 6 9 Control 39 64 M 2 12
AD 40 60 F 6 5 Control 40 62 M 0 4
Average 75.60 3 (F): 7 (M) 5.50 8.55 77.00 3 (F): 7 (M) 1.90 9.20
Table 3
Alzheimer’s disease (AD) and control cases used in immunohistochemical analysis of hBCATc and hBCATm. All cases chosen had a postmortem
(PM) delay of less than 72 h, had no significant comorbidities (such as vascular dementia or Parkinson’s disease) and were age- and gender-
matched
Case Age Sex Braak PM delay Case Age Sex Braak PM delay
AD 1 85 M 6 50 Control 1 85 M 2 31
AD 2 95 F 5 28 Control 2 95 F 4 10
AD 3 89 F 5 28 Control 3 89 F 3 47
AD 4 86 F 5 72 Control 4 87 F 3 47
AD 5 69 M 6 72 Control 5 69 M 2 66
AD 6 65 M 5 39 Control 6 64 M 0 16
AD 7 85 M 5 60 Control 7 86 M 3 16
AD 8 95 M 4 27 Control 8 94 M 2 40
AD 9 80 M 4 24 Control 9 80 M 0 46
AD 10 88 F 6 64 Control 10 88 F 2 28
AD 11 89 F 6 4 Control 11 89 F 2 15
AD 12 80 F 5 51 Control 12 80 F 0 39
AD 13 78 M 6 49 Control 13 77 M 1 42
AD 14 87 M 6 36 Control 14 87 M 2 24
AD 15 93 M 6 20 Control 15 93 M 3 38
AD 16 74 M 5 24 Control 16 73 M 3 35
AD 17 76 M 5 11 Control 17 76 M 2 23
AD 18 78 M 6 50 Control 18 78 M 1 48
AD 19 71 F 5 67 Control 19 72 F 0 24
AD 20 74 F 6 12 Control 20 73 F 1 59
AD 21 93 F 5 60 Control 21 93 F 1 15
AD 22 73 M 5 17 Control 22 73 M 1 33
AD 23 78 F 6 21 Control 23 78 F 1 22
AD 24 69 M 5 12 Control 24 70 M 2 50
AD 25 96 F 4 53 Control 25 94 F 2 21
AD 26 79 M 6 28 Control 26 80 M 3 67
AD 27 78 M 5 22 Control 27 78 M 2 12
AD 28 88 M 5 3 Control 28 90 M 2 45
AD 29 71 M 6 30 Control 29 71 M 1 25
AD 30 83 F 5 5 Control 30 83 F 2 24
Average 81.50 12 (F): 18 (M) 5.30 34.63 81.50 12 (F): 18 (M) 1.77 33.60
homogenization, 1 mL of protein homogenization
buffer (1% SDS, 0.1 M NaCl, 10 mM Tris HCl pH 7.6,
1M PMSF, and 1 mg/L aprotinin) was added to each
sample and homogenized for 15 s × 2 using a Precellys
24 lysis homogenizer. The tubes were centrifuged at
13,000 rpm at 4◦C for 15 min. Following centrifuga-
tion, 50L aliquots of the supernatant were prepared
and assayed for protein concentration using the Brad-
ford method. These samples were subsequently stored
at −80◦C before western blot analysis.
Immunofluorescence
Sections were placed in a 60◦C oven overnight
prior to immunohistochemistry and immunofluores-
cence to aid adhesion. The sections were subsequently
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dewaxed in clearene (2 × 5 min) and dehydrated in
100% ethanol (2 × 3 min). Following dehydration, sec-
tions were pre-treated using EDTA (1 mM EDTA,
0.05% Tween 20, pH 8.0) prior to blocking with horse
serum (1/10 dilution in PBS). Sections were incu-
bated for 20 h with primary antibody (1/50 for hBCATc
and 1/100 for MAP2). Subsequently, the slides were
washed in PBS (2 × 3 min) and incubated in species
specific secondary antibody (1/1000 for Alexafluor
488 and 647) in the dark for 60 min. The slides were
washed in deionized water (2 × 5 min) and mounted in
aqueous mountant. Images were acquired using Andor
IQ software (Cairn Research Ltd, Faversham, UK) and
a confocal Nikon Eclipse 80i microscope.
Immunohistochemistry
Initial section treatment occurred in an identical
manner to immunofluorescence. After dehydration,
endogenous peroxidase was quenched in 0.9% hydro-
gen peroxide/methanol solution for 30 min at room
temperature. Standard immunohistochemistry was
performed as per Vectastain ABC protocol (with
citrate pre-treatment and 20 h primary antibody
incubation) prior to immersion in copper sulphate
(16 mM CuSO4.5H2O, 0.123 M NaCl) for 4 min
and counterstaining with Harris’s hematoxylin (25%
Gill hematoxylin). The slides were dehydrated in
100% ethanol (2 × 5 min), cleared in 100% clearene
(2 × 3 min), and mounted in clearium. Sections were
viewed, scored, and imaged on a Nikon Eclipse 50i and
80i microscope.
Scoring protocol
For anatomical reference, labelling was scored in
the same region of each section: the collateral sulci of
the temporal lobe and the overlying cortex and areas
CA1 and CA4 of the hippocampus. The sections were
examined under a 20× objective and the degree of
labelling designated on an arbitrary semi-quantitative
scale: 0 = no labelling, 1 = weak labelling of occasional
cells (<10 cells), 2 = labelling of many cells (15–30
cells), 3 = strong labelling of many cells (30+ cells).
Labelling was scored according to cell type: neuronal
for hBCATc and vascular for hBCATm.
For histometric image analysis, slides were imaged
using a Nikon 80i and analyzed using NIS imaging
software for the area of image labelled and mean pixel
density, to give an integrated density. This was per-
formed on the CA4 region at ×10 magnification.
Overexpression of hBCAT proteins
The overexpression and purification of the hBCAT
proteins are described in Davoodi et al. [30]. In brief,
using E. coli BL21DE3 cells transformed with pET-
28a, N-terminal 6× histidine tagged hBCAT-cDNA
vectors, hBCAT proteins were overexpressed follow-
ing induction with 1 M IPTG. Following extraction and
affinity purification using nickel-NTA agarose (Qia-
gen Ltd, West Sussex), the N-terminal 6× histidine
affinity tag was cleaved by (100 NIH units) throm-
bin. Final purification of each hBCAT isoform was
obtained using a HiTrapTM Q HP strong anion col-
umn (GE Healthcare, Buckinghamshire). The purified
hBCAT proteins were dialyzed at 4◦C overnight into
storage buffer (50 mM Tris pH 7.4, 150 mM NaCl,
5 mM glucose, 1 mM EDTA, 1 mM -ketoisocaproate
(KIC), 5 mM DTT) and stored at −20◦C (in 30%
w/v glycerol). The concentration of purified protein
was determined using the Schaffner and Weissmann
method [31], where the estimated yield was 10 mg of
purified protein/L of E. coli. Using 12% SDS-PAGE
and quadruple time of flight mass spectrometry purity
of each isoform was determined to be >98%.
Western blot analysis
Aliquots of overexpressed protein were calculated
to each standard concentration using the Schaffner and
Weissmann method [31] and in NuPAGE® LDS sam-
ple buffer (4×) and loaded on to a NuPAGE® Novex®
4–12% Bis-Tris 1 mm gel. Proteins were separated
with 1× NuPAGE® MES SDS Running Buffer for
1 h at 200 volts. For subject samples, 20g of pro-
tein from each supernatant was used. The gels were
prepared for immunoblotting using the SNAP ID sys-
tem (Millipore). The membranes were blocked with
0.5% non-fat milk powder in TBST (0.05% Tween20
in Tris buffered saline – 0.02 M Tris, 0.5 M NaCl,
pH 7.5). Primary antibody (1/1000 for hBCATc and
GAPDH, and 1/1500 for hBCATm) was prepared in
0.5% non-fat milk powder in TBST and added for
10 min prior to several washes with TBST. Secondary
antibody (1/5000) linked with HRP, was added for
10 min and then washed with TBST. The positive
bands were visualized using chemiluminescent HRP
substrate. GBX developer and fixer were used for 10
and 20 s respectively. Integrated area densitometry was
carried out with using ImageJTM. These results were
measured in relation to the GAPDH loading control.
For re-probing, membranes were incubated with 0.5
M NaOH (7 min) and washed in TBST (3 × 10 min).
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The membrane was subsequently treated from block-
ing step.
RESULTS
Regional increase of hBCATc expression in AD
brain relative to matched controls
Immunohistochemistry and western blot analysis
was used to evaluate the differential expression of
hBCATc in the hippocampus, frontal, and temporal
cortex of AD brain relative to matched controls (Figs. 2
and 3). Using histometric semi-quantitative scoring,
a significant increase (p = 0.026) in hBCATc expres-
sion was observed, with intense staining of neurons
(25/30 cases) in the CA4 region of AD relative to
matched controls brains (Fig. 2A-2D). Labelling of
hBCATc was restricted to neurons as illustrated using
the neuronal specific marker, microtubule-associated
protein 2 (Supplementary Figure 1) [26]. A significant
increase (p = 0.011) in immunopositive neuronal cells
for hBCATc in the CA1 region of the hippocampus
was also reported (Fig. 2E–H). Western blot anal-
ysis supported these findings, which confirmed that
there was a significant increase in hBCATc in the hip-
pocampus of AD relative to matched controls (Fig. 2I,
J). The densitometry of hBCATc was calculated rel-
ative to the corresponding GAPDH density, which
showed no alteration between AD and control brains
(Supplementary Figure 2). Moreover, to evaluate the
impact of postmortem delay on hBCAT expression,
we assessed the expression of both hBCAT proteins
Fig. 2. Increased hBCATc expression in the hippocampus of AD brains. CA4 region of the hippocampus in a control (A) and AD brain (B)
showing intensely labelled neurons (large arrows) and the granule cell layer (dotted line). CA1 region of the hippocampus in a control (E) and
AD (F) subject showing intensely labelled neurons (large arrows). C, D, G, H) The slides were scored on a 0–3 scoring system and analyzed for
significance using the Wilcoxon-Mann-Whitney test in Minitab™ as described in materials and methods. I) Western blot analysis of hippocampal
tissue. The density of each band was measured using ImageJTM software (Wayne Rasband, National Institute of Health, USA) and analyzed for
significance using a one-way ANOVA test in Minitab™. J) Interquartile range (box) sample variability (whiskers) and the median (horizontal
line within the interquartile range) are shown. Magnification for A, B, E, and F, ×10. Scale bar: 200m.
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Fig. 3. Immunohistochemistry and western blot analysis of hBCATc in the frontal and temporal cortex of AD and control brains. Collateral
sulci (CS*) region of the temporal cortex in a control (A) and AD brain (B). Molecular and nuclear layer of the cerebellum in a control (E) and
AD (F) brain. C, D, G, H) The slides were scored on a 0–3 scoring system and analyzed for significance using the Wilcoxon-Mann-Whitney
test in Minitab™. Western blot analysis of temporal cortex homogenate (I) and the frontal cortex (L). The density of each band was measured
using ImageJTM software (Wayne Rasband, National Institute of Health, USA) and analyzed for significance using a two-way ANOVA test in
Minitab™. J, K, M, N) Interquartile range (box) sample variability (whiskers) and the median (horizontal line within the interquartile range).
Magnification for A, B, E, and F, X10. Scale bar: 200m.
over time, where no change was observed, indicating
that postmortem delay does not impact the expression
of these proteins (Supplementary Figure 3).
Although positive staining was reported throughout
the frontal and temporal regions, it was not as intense
as observed in the hippocampal region and there was
no significant increase in staining in the collateral
sulci region (Fig. 3A–D, p = 0.496). As expected, there
was also no difference in labelling for hBCATc in
the cerebellum of AD subjects relative to matched con-
trols, an area not affected by AD pathology (Fig. 3E–H,
p = 0.545). Using a two-way ANOVA analysis of
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Fig. 4. Widespread increase in hBCAT expression in AD brain. Vessels of the temporal cortex in a control (A) and AD brain (B). White matter
of the cerebellum in a control (E) and AD (F) brain. C, D, G, H) The slides were scored on a 0–3 scoring system and analyzed for significance
using the Wilcoxon-Mann-Whitney test in Minitab™. Western blot analysis of hBCATm in temporal cortex homogenate (I) and frontal cortex
(L). The density of each band was measured using ImageJTM software (Wayne Rasband, National Institute of Health, USA) and analyzed for
significance using a two-way ANOVA test in Minitab™. J, K, M, N) Interquartile range (box) sample variability (whiskers) and the median
(horizontal line within the interquartile range) are shown. Magnification for A and B, X40; for E and F, X10. Scale bar: A and B, 50m; E and
F, 200m.
western blot data, these observations were upheld,
where western blot data correlated with histomet-
ric analysis (Fig. 3I–N and Supplementary Figure 4,
respectively). These studies indicate that there is a
regional increase in hBCATc expression, the area most
affected by AD pathology.
Increased hBCATm expression in AD brain was
more widespread than for hBCATc
As previously described, labelling of hBCATm was
largely restricted to blood vessels, throughout all brain
areas (Fig. 4A–H) [26]. Here, a significant increase
AU
TH
OR
 C
OP
Y
900 J. Hull et al. / Upregulation of the BCAT Proteins in the Human Brain
Fig. 5. Box and whisker plots of hBCAT expression correlated with Braak stage. A, B) Box and whisker plots of hBCATc. C, D) Box and
whisker plots of hBCATm. Protein expression was estimated relative to GAPDH using densitometry analysis as described in materials and
methods and correlated with Braak stage. Panels show interquartile range (box) sample variability (whiskers) and the median (horizontal line
within the interquartile range).
in hBCATm staining (p = 0.025) was observed in the
temporal cortex of AD brain relative to matched con-
trols, which correlated with western blot analysis
(p = 2.79 × 10−5) (Fig. 4A–D and I-J, respectively).
Increased hBCATm expression was also observed in
the CA1 and CA4 of the hippocampal region (Sup-
plementary Figure 5). Similar to that reported for
hBCATc, there was no increase in hBCATm expres-
sion in the cerebellum (Fig. 4E–H, p = 1.0). Two-way
ANOVA analysis of hBCATm expression in the frontal
cortex also showed a significant increase in expression
(Fig. 4L–M, p = 4.22 × 10−4). Analysis of brain sam-
ples with a ≤15 h postmortem delay also showed a
significant increase in hBCATm expression in the tem-
poral and frontal cortex (Fig. 4K and N, respectively).
Increased hBCATm expression correlated with
Braak stage
Box and whisker plots were used to evaluate if
increased hBCAT expression correlated with Braak
stage or gender. No correlation was observed between
hBCATc protein density and Braak stage (Fig. 5A,
B). However, as observed in Fig. 5C and D there
is a positive correlation between hBCATm relative
protein density and the corresponding Braak stage
for each patient in the frontal and temporal region.
Here, a trend is observed showing an increase in
Braak stage, especially at stages 4–6 when com-
pared to 0–3 as hBCATm density increases, and this
is reflected in the Spearman’s rank correlation of
+0.469 (frontal, p = 5.63 × 10−6) and 0.406 (temporal,
p = 9.29 × 10−5).
A two-way ANOVA did not show any significant dif-
ferences between sex for both hBCATc and hBCATm
in frontal and temporal regions (Fig. 6). However, as
expected in the frontal region, male and female AD
patients had a significantly higher hBCATm expres-
sion compared to male controls (Fig. 6C, p = 0.008 and
0.004, respectively) and a similar pattern was observed
in the temporal region (Fig. 6D, p = 0.004 and 0.008,
respectively).
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Fig. 6. Tukey Post-hoc analysis of two-way ANOVA (<72 h cohort). Concentrations of hBCATc (A,B) and hBCATm (C,D) proteins were
estimated using densitometry analysis and analyzed according to gender and disease state. There was no significant difference observed for
hBCATc in either variable, but the concentration of hBCATm in both the frontal and temporal cortex was significant when comparing control
males with either the AD females (C and D, p = 0.004 and 0.008, respectively) or AD males (C and D, p = 0.008 and 0.004, respectively).
S-glutathionylated hBCATm is more evident in AD
brain relative to matched controls
Western blot analysis demonstrated that there was
also evidence of differential post-translation modifica-
tion of hBCATm that was more evident in AD subjects
relative to matched controls (Fig. 4I, L (arrow)). Pre-
vious work by this group has demonstrated that the
hBCAT proteins have a redox-active CXXC motif that
is regulated through changes in the redox environment
[32–36]. In particular, these proteins are suscepti-
ble to differential S-glutathionylation [35]. Here, we
show that the banding pattern observed here reflects
S-glutathionylation adducts (Fig. 7), which is more
pronounced in AD brain relative to matched controls.
DISCUSSION
Glutamate toxicity and necrotic cell death have
been implicated in the pathogenesis of ischemia, brain
hypoxia, and several neurodegenerative conditions
including AD and amyotrophic lateral sclerosis [2,
3]. This toxicity is considered to be exacerbated by
energy deprivation and ischemic conditions, indicat-
ing that dysfunction of energy metabolic pathways
Fig. 7. Western blot analysis of glutathione (GSH) in the hippocam-
pus of AD and control brains. Western blot analysis was performed
as described in the Materials and Methods using antibodies specific
to S-glutathionylation (1/1000).
may be responsible [37–39]. Although it is evident
that the release of large concentrations of glutamate
into the extracellular fluid can occur under pathogenic
conditions, the source of this glutamate has been met
with extensive debate [9]. However, given that the
highest concentration of glutamate is stored in neu-
ronal rather than glial cells, glutamatergic neurons in
particular are considered the most likely source. As
hBCATc is specifically expressed in glutamatergic and
GABAergic neurons and is responsible for catalyzing
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nitrogen shuttling, required for glutamate synthesis it is
important to understand if this pathway is dysregulated
in neurodegenerative conditions such as AD. In the
present study we have shown for the first time that the
expression of the hBCAT enzymes, which regulate the
concentration of BCAA and glutamate, show a regional
increased expression in AD relative to matched control
brains. The upregulation of hBCATm correlated with
Braak stage, suggesting that the level of this enzyme
is directly related to the progression of the disease.
Although studies of cell and animal models suggest
that increased concentrations of BCATs may, at least
initially, be neuroprotective (see below), BCATs within
the brain may increase the production of glutamate and
exacerbate neuronal excitotoxicity, potentially con-
tributing to cell death. Altered BCAA metabolism may
also contribute to neuronal dysfunction through other
mechanisms (e.g., alteration in the concentration of
leucine, which regulates several metabolic pathways,
such as the mTOR pathway [40]) but the possible
contribution of these processes to AD has yet to be
investigated.
Upregulation of hBCATc has previously been
reported in rodent models investigating neuronal cell
death. Brain-derived neurotrophic factor (BDNF), an
important factor in mediating neuronal survival, was
shown to prevent degeneration of dorsal lateral genic-
ulate nucleus neurons in newborn rats with visual
cortex ablation [41]. In response to BDNF treatment,
mRNA fingerprinting showed that BCATc was signif-
icantly upregulated, particularly but not exclusively to
astrocytes, a curious finding as BCATc is specifically
expressed in neuronal cells [42]. In a separate study,
the authors demonstrated that upregulation of BCATc
mRNA in adult BNDF transgenic mice was particular
to the parietal cortex, the hilus, and CA3 hippocampal
subfield [43]. This upregulation was restricted to these
areas with no reported difference in BCATc expression
in the thalamus, the habenula, and the cerebellum. In
our study, regional increases in expression were also
observed, where increased concentrations of hBCATc
showed a significant increase in the hippocampal
region of the brain, specifically the CA1 and CA4
region, whereas a significant increase in the frontal
or temporal region was not noted. These regional
increases support a role for hBCATc in neuronal sur-
vival in areas heavily populated with glutamatergic
neurons and indicate that BCAT metabolic activity is
differentially regulated in these areas.
Our current knowledge of how the gluta-
mate/glutamine cycle is dysregulated in AD may offer
insight into why there is an increase in hBCATc
expression. Synaptic glutamate excess, which causes
neuronal cell death in AD, is partly due to the
reduced ability of astrocytes to take up glutamate,
because the glutamate transporter (GLT-1/EAAT2) is
modified through oxidation [44, 45]. An altered glu-
tamate/glutamine cycle in AD is also supported by
findings of reduced neurotransmitter levels, e.g., glu-
tamate and GABA, in the brains of patients with AD
relative to age-matched controls, whereas the concen-
tration of glutamine was found to be increased [46].
If levels of glutamate recovered from the synapse are
reduced, this will compromise the replenishment of
glutamate stores in neuronal cells, which may indi-
cate why glutamate levels were found to be low in
AD brain. In our studies, the reported increase in
hBCATc expression may be an attempt by the cell to
compensate for this lost glutamate, thus acting in a
neuroprotective capacity. A neuroprotective role has
also been suggested in other models of brain injury,
where Kholodilov et al. demonstrated that BCATc
was upregulated in the substantia nigra of rat follow-
ing developmental striatal target injury [47]. In this
instance, despite the fact that upregulation correlated
with the extent of cell death, a neuroprotective role was
suggested because the neurons that were immunopos-
itive for BCATc had normal morphology, with no
evidence of apoptotic features. It is possible that in
AD too, the upregulation of hBCAT is a physiological
response, possibly to oxidative stress (which BCAAs
may exacerbate), and in general the neurons that were
immunopositive for hBCATc in the human brain tissue
also appeared morphologically intact.
Although glutamate is controlled through several
metabolic pathways and its levels can be influenced
by changes in any of these [48], increased levels of
hBCATc would be expected to expand the neuronal
pool of glutamate [24, 29, 49]. In this context, as
evidenced by the immunohistochemistry data, it may
be relevant that the intensity of hBCATc labelling in
both cell bodies and dendrites was most pronounced
in the hippocampus, a region that is known to be
particularly susceptible to excitotoxic neuronal injury
[50] and is affected severely and at an early stage of
AD. Also, the anti-epileptic drug gabapentin, which
inhibits hBCATc [51], has proved successful in treating
behavioral alterations in subjects with AD [52, 53].
Although hBCATc was not identified as the specific
target and further clinical trials would be required
to evaluate the utility of gabapentin for treating AD,
these reports indicate a potential target for future
drug therapies. Altered hBCAT expression or BCAA
metabolism has also been reported in several other
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neurodegenerative conditions [54–56]. In addition, to
the potential toxicity of glutamate, the -keto acids
generated would also create unfavorable conditions for
cell survival if these accumulated. The adverse con-
sequences of abnormally increased levels of -keto
acids and BCAAs are manifested in the clinical con-
dition maple syrup urine disease [20]. High levels of
these metabolites have been associated with inhibi-
tion of cell proliferation and a prolonged increase in
the G1 stage of the cell division cycle [57]. Neuronal
cell models have demonstrated that increased expo-
sure to KIC results in a decrease in cell viability and
a loss of cell morphology [58]. Thus, left unregulated,
increased levels of hBCATc in neuronal cells of the
hippocampus could contribute to a loss in cell viability
compromising neuronal function.
In human brain, the mitochondrial isoform is abun-
dant in the endothelial layer of the cerebral vasculature
[26] and here shows significant upregulation in AD.
Brain glutamate is primarily controlled via the gluta-
mate/glutamine cycle but recently studies supporting
the importance of the endothelium in this regula-
tion are gaining impetus [59]. In a study using a
bovine endothelial/rat astrocyte coculture model, the
Km value of transendothelial glutamate efflux was
estimated at 138M [59]. Under pathophysiological
conditions such as ischemia, traumatic head injury, or
in some neurodegenerative conditions (including AD),
where levels of glutamate are estimated to rise con-
siderably (up to 200M), the proposed blood-brain
barrier-efflux system could potentially assist in the
control of brain glutamate concentrations. Here we
propose that when toxicity features, there is increased
expression of hBCATm to metabolize this excess glu-
tamate, offering support to astrocytes. However, we
have shown that hBCATm levels correlate with Braak
stage, and over time sustained overproduction of glu-
tamate and -keto acids may contribute to neuronal
dysfunction and damage.
Evidence of post-translational modifications of
hBCATm was observed in brain homogenates with
increased levels evident in AD brain. The hBCAT pro-
teins are redox sensitive proteins that are susceptible
to oxidation, S-nitrosation, and S-glutathionylation,
modifications which arise due to changes in the redox
environment [32–38]. Changes in cellular stress are
intrinsically linked with the pathogenesis of sev-
eral neurodegenerative diseases including AD. All
enzymes of the glutaredoxin system, involved in cel-
lular repair, have been shown to be upregulated in
neuronal cells in response to oxidative stress and
this correlates with widespread S-glutathionylation
[60]. Here, increased S-glutathionylation of hBCATm
occurs in human brains; S-glutathionylation of overex-
pressed hBCAT in vitro shows evidence of upper bands
as the redox environment becomes more oxidizing,
which could explain the post-translational modifica-
tions seen here. Proteins modified through oxidation
and S-nitrosation reported in other studies using AD
brains have been shown to be functionally affected,
compromising their role in particular under pathogenic
conditions, which could also be true for hBCAT
[6, 60].
In conclusion, this study has clearly demonstrated
that the levels of the hBCAT proteins are increased in
postmortem AD brain samples, with hBCATm levels
correlating with Braak stage indicating a correlation
with disease progression and severity. Increased levels
of these proteins may initially be part of a neuropro-
tective cellular response. However, products of their
metabolism, glutamate, and the -keto acids are neu-
rotoxic, which may compromise this neuroprotective
role, potentially contributing to neuronal cell death.
The mechanisms which govern the post-translational
modification of the proteins are unclear and require
additional investigation. Further studies are needed to
ascertain whether reduction of hBCAT levels or activ-
ity has the potential to reduce neuronal damage and
improve outcome in AD.
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